会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Vitronectin receptor antagonist pharmaceuticals
    • Vitronectin受体拮抗剂药物
    • US20050154185A1
    • 2005-07-14
    • US10770380
    • 2004-02-02
    • Milind RajopadhyeThomas HarrisEdward Cheesman
    • Milind RajopadhyeThomas HarrisEdward Cheesman
    • A61K49/00C07D401/12C07D401/14C07K5/02C07K5/06C07K5/078C07K5/12C07D471/02C07D487/02
    • C07D401/14A61K49/0002C07D401/12C07K5/0205C07K5/0215C07K5/06139C07K5/06191
    • The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    • 本发明描述了新的下式化合物:<?in-line-formula description =“In-line Formulas”end =“lead”?>(Q) 对于癌症的诊断和治疗有用的<?in-line-formula description =“在线公式”end =“tail”?>,肿瘤成像方法 患者,以及在患者中治疗癌症的方法。 本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。 本发明还提供了用于成像动脉粥样硬化,再狭窄,心脏缺血和心肌再灌注损伤的新型化合物。 本发明还提供了可用于治疗类风湿性关节炎的新化合物。 药物由与血管发生期间上调的受体结合的靶向部分,任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。 可成像部分是伽马射线或正电子发射放射性同位素,磁共振成像造影剂,X射线造影剂或超声造影剂。
    • 5. 发明申请
    • Regeneration of ionic liquid catalyst by hydrogenation using metal and acid
    • 使用金属和酸通过氢化再生离子液体催化剂
    • US20070142217A1
    • 2007-06-21
    • US11316629
    • 2005-12-20
    • Saleh ElomariThomas Harris
    • Saleh ElomariThomas Harris
    • B01J27/125B01J27/06B01J31/00
    • B01J27/32B01J27/125B01J31/0278B01J31/0284B01J31/0287B01J31/0288B01J31/40C07C2/862Y02P20/584
    • A process for regenerating a used acidic ionic liquid catalyst which has been deactivated by conjunct polymers comprising combining the used catalyst, a metal and a Broensted acid which acts a source of hydrogen in a reaction zone under hydrogenation conditions for a time sufficient to hydrogenate at least a portion of the conjunct polymer is disclosed. An embodiment of a process for regenerating a used acidic ionic liquid catalyst which has been deactivated by conjunct polymers comprising the steps of combining the used ionic liquid catalyst, a metal and HCl in a reaction zone under hydrogenation conditions for a time sufficient to hydrogenate at least a portion of the conjunct polymer; removing reaction product from the reaction zone; mixing the removed reaction product with a hydrocarbon solvent in which the hydrogenated conjunct polymers are soluble; allowing the mixture to separate into two phases, a lighter phase which contains the hydrogenated conjunct polymers and a heavier phase which contains a regenerated ionic liquid catalyst; and recovering at least a portion of the heavier phase is also disclosed.
    • 一种再生使用的酸性离子液体催化剂的方法,其已经通过结合聚合物失活,包括将氢化条件下的反应区中使用的催化剂,金属和作为氢源的布朗斯台德酸组合至少足以氢化至少 公开了一部分结合聚合物。 用于再生已使用的结合聚合物失活的酸性离子液体催化剂的方法的一个实施方案包括以下步骤:在氢化条件下将反应区中使用的离子液体催化剂,金属和HCl组合至少足以氢化至少 结合聚合物的一部分; 从反应区除去反应产物; 将除去的反应产物与其中氢化结合聚合物可溶的烃溶剂混合; 允许混合物分离成两相,其中较轻的相含有氢化结合聚合物和较重相,其含有再生离子液体催化剂; 并且还公开了至少一部分较重相的回收。